Amantadine for COVID-19.

Grieb, Pawel; Swiatkiewicz, Maciej; Prus, Katarzyna; Rejdak, Konrad

Grieb, Pawel; Swiatkiewicz, Maciej; Prus, Katarzyna; Rejdak, Konrad.

Grieb P; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Swiatkiewicz M; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Prus K; Department of Neurology, Medical University of Lublin, Lublin, Poland.
Rejdak K; Department of Neurology, Medical University of Lublin, Lublin, Poland.

J Clin Pharmacol ; 61(3): 412-413, 2021 03.

Article in English | MEDLINE | ID: covidwho-1064375

Subject(s)

Amantadine/therapeutic use; Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; COVID-19/epidemiology; Surveys and Questionnaires; Fatigue/drug therapy; Fatigue/epidemiology; Humans; Multiple Sclerosis/drug therapy; Multiple Sclerosis/epidemiology; Parkinson Disease/drug therapy; Parkinson Disease/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Amantadine / Surveys and Questionnaires / COVID-19 / COVID-19 Drug Treatment Type of study: Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Jcph.1802

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google